Talis Biomedical Corporation (TLIS)

Talis Biomedical Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue Revenue Growth	0.41	2.13	4.81	8.19	10.94	3.98
Revenue Growth	-85.69%	-55.65%	-41.27%	-25.10%	175.03%	66.40%
Gross Profit Gross Profit Growth	-20.09	-38.6	-74.41	-149.4	-78.08	-19.84
Operating Income Operating Income Growth	-46.35	-64.05	-111.55	-191.82	-91.18	-26.7
Net Income Net Income Growth	-51.03	-62.01	-113.01	-192.04	-91.13	26.38
Earnings Per Share EPS Growth	-28.02	-34.12	-62.77	-127.15	-644.69	-191.62
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Grant Grant Growth	1.72	1.16
Antigen Tests Products Antigen Tests Products Growth	0.41	3.65

Cash & Debt

Chart

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Investments Cash & Investments Growth	59.87	76.73	130.19	232.55	138.48	21.6
Total Debt Total Debt Growth	18.8	19.67	33.58	13.98	0.69	-
Net Cash (Debt) Net Cash Growth	41.07	57.06	96.61	218.57	137.79	21.6
Net Cash Growth	-47.23%	-40.93%	-55.80%	58.62%	537.80%	213.33%
Net Cash Per Share Net Cash Per Share Growth	22.55	31.40	53.66	144.71	974.78	150.68

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Cash Flow Operating Cash Flow Growth	-40.26	-53.24	-100.14	-171.38	-87.02	-24.33
Capital Expenditures CapEx Growth	0.02	-0.49	-1.62	-2.87	-8.2	-0.58
Free Cash Flow Free Cash Flow Growth	-40.24	-53.73	-101.75	-174.25	-95.23	-24.9
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Margin	-11360.29%	-3001.36%	-2318.08%	-2341.22%	-833.64%	-671.34%
Pretax Margin	-12506.37%	-2905.67%	-2348.55%	-2343.90%	-833.15%	-690.82%
Profit Margin	-12506.37%	-2905.67%	-2348.55%	-2343.90%	-833.15%	663.36%
FCF Margin	-9861.52%	-2517.62%	-2114.53%	-2126.82%	-870.59%	-626.20%

Valuation

Chart

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Aug 8, 2026	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
PS Ratio	12.69	6.36	2.48	12.87	-	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2024

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Dec 18, 2025

Data Sources Report a data error